Behind
Every Technology
There is a team

IQ Biozoom, a Polish company at the forefront of non-invasive health monitoring technology, is making significant strides with its innovative approach to measuring biochemical substances in the body. Recently, the company secured investment from the venture capital fund VC Link, which supports groundbreaking technologies with global potential.

Founded in 2021, IQ Biozoom is developing a cutting-edge technology designed to measure biomarkers such as glucose, lactates, cholesterol, hormones, and CRP proteins without invasive procedures. This is achieved through an advanced biosensor that uses stream-printed semiconductor devices, including thin-film transistors. Unlike traditional glucose meters that require blood samples, IQ Biozoom's technology leverages saliva, sweat, urine, or tears for measurements.

The need for such technology is underscored by a report titled “Polska Rodzina z cukrzycą,” published by the Polish Diabetes Education Association (SED). According to this report, 84% of people with Type 1 diabetes prefer non-invasive glucose monitoring methods, but 60% skip some daily tests due to the discomfort and infection risks associated with finger pricking. IQ Biozoom’s solution aims to address these concerns by providing a more comfortable and hygienic alternative.

The company’s device operates with disposable test strips, which are designed to measure different biomarkers. The versatility of this technology allows one device to use various test strips, potentially measuring glucose, CRP proteins, cortisol, lactates, and more. This flexibility reduces the cost of additional diagnostic tools and makes it easier to expand the range of measurable biomarkers.

Dr. Jakub Kaczmarski, a co-founder and Chief Technology Officer at IQ Biozoom, highlights that the technology enables measurements with up to ten times the accuracy of current market standards for glucose monitoring. This high precision is particularly beneficial for detecting very low concentrations of biomarkers or identifying health disorders early on.

In the third quarter of 2023, IQ Biozoom received funding from VC Link, a fund specializing in advanced industrial technologies and materials engineering. Grzegorz Putynkowski, president of VC Link, praised the technology’s market potential and its contribution to future medical advancements. The investment supports IQ Biozoom’s ongoing research and development efforts, including collaboration with esteemed institutions like the University of Cambridge, University of Surrey, and Kochi University of Technology.

Currently, IQ Biozoom is in its seed funding round and aims to finalize its development for glucose and lactate testing, followed by obtaining the necessary certifications. The company’s technology is also in the process of patent protection in Europe, China, and the United States.

The global market for home diagnostics is growing rapidly, with an annual increase of 5.6% and an expected value surpassing $13.6 billion by 2033. IQ Biozoom is positioned to make a significant impact in this sector by enhancing the accessibility and convenience of health monitoring.

For more detailed information, you can read the full article here: IQ Biozoom: Bezinwazyjne pomiary glukozy w domu już wkrótce.